Focused on expanding its leadership in arrhythmia diagnostics, the company leverages validated ECG solutions and AI to support early stroke prevention. Growth is driven by new contracts in core European markets and a secured rights issue of 15.7 MSEK.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.